Skip to main content
. 2021 Jan;10(1):10–22. doi: 10.21037/gs-20-486

Table 4. Comparisons in patients with 3 identified parathyroid glands.

Characteristics In situ preservation (N=74) Autotransplantation (N=138) P
Age, years 41.65±12.85 40.73±12.90 0.622
Sex (male) 19 40 0.608
BMI 22.48±3.30 23.30±3.63 0.109
NG 39 67 0.666
HD 22 48 0.540
Hypertension 8 16 0.864
Diabetes 1 5 0.606
Hypothyroidism 2 2 0.912
Hyperthyroidism 3 4 0.654
Tumor size (mm) 14.86±9.03 14.06±7.84 0.513
Multifocality 17 41 0.302
Capsule invasion 34 60 0.730
TNM stage
   Tx/t1/t2/t3/t4 0/36/3/34/1 1/65/8/59/5 0.889
   Nx/N0/n1a/n1b 0/26/34/14 1/43/52/42 0.232
Hypoparathyroidism
   Transient 29/74 (39.2%) 87/138 (63.0%) 0.001*
   Permanent 2/74 (2.7%) 1/138 (0.7%) 0.581
PTH (pg/mL)
   Preoperative 42.03±10.17 44.55±9.72 0.079
   1-day 17.91±10.80 14.22±9.54 0.011*
   1-month 31.59±12.15 29.07±11.07 0.162
   3-month 37.62±16.20 31.59±12.15 0.103
   6-month 34.02±14.67 33.66±12.24 0.917
   12-month 42.03±17.01 32.85±11.70 0.026*
   24-month 29.79±18.09 34.29±11.07 0.457
PTH <14 pg/mL
   1-day 28 (37.8%) 87 (63.5%) <0.001*
   1-month 3 (4.9%) 9 (7.3%) 0.762
   3-month 1 (5.6%) 1 (2.0%) 1.000
   6-month 1 (5.3%) 0 (0%) 0.637
   12-month 1 (5.9%) 1 (2.8%) 1.000
   24-month 1 (16.7%) 0 (0%) 0.496
Ca (mg/dL)
   Preoperative 9.40±0.44 9.32±0.44 0.264
   1-month 9.36±0.48 9.16±0.52 0.004*
   3-month 8.96±0.68 8.92±0.56 0.763
   6-month 8.92±0.68 9.04±0.72 0.258
   12-month 9.00±0.52 9.00±0.60 0.988
   24-month 9.16±0.84 8.96±0.48 0.313
Ca 8.5 mg/dL
   1-month 3 (4.5%) 10 (8.0%) 0.549
   3-month 8 (19.5%) 15 (17.4%) 0.777
   6-month 8 (21.1%) 9 (11.3%) 0.157
   12-month 3 (9.7%) 9 (13.8%) 0.805
   24-month 2 (11.1%) 5 (14.3%) 1.000

*, significantly statistical differences; , the difference of PTH levels between preoperative and postoperative 12-month in patients with autotransplantation reached statistical significance. BMI, body mass index; HD, Hashimoto’s disease; NG, nodular goiter; TNM, tumor node metastasis; PTH, parathyroid hormone; Ca, calcium.